FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2148882827> ?p ?o ?g. }

• W2148882827 endingPage "7280" @default.
• W2148882827 startingPage "7273" @default.
• W2148882827 abstract "SL3-3 is a highly T-lymphomagenic murine retrovirus. The major genetic determinant of disease is the transcriptional enhancer, which consists of a repeated region with densely packed binding sites for several transcription factors, including AML1 (also known as core binding factor and polyoma enhancer-binding protein 2) and nuclear factor 1 (NF1). Previously, we examined the enhancer structure of proviruses from murine tumors induced by SL3-3 with mutated AML1 (core) sites and found a few cases of second-site alterations. These consisted of deletions involving the NF1 sites and alterations in overall number of repeat elements, and they conferred increased enhancer strength in transient transcription assays. We have now tested the pathogenicity of a virus harboring one such second-site variant enhancer in inbred NMRI mice. It induced lymphomas with a 100% incidence and a significantly shorter latency than the AML1 mutant it evolved from. The enhancer structure thus represents the selection for a more tumorigenic virus variant during the pathogenic process. Sequencing of provirus from the induced tumors showed the new enhancer variant to be genetically stable. Also, Southern blotting showed that the tumors induced by the variant were T-cell lymphomas, as were the wild-type-induced lymphomas. In contrast, tumors induced by the original core/AML1 site I-II mutant appeared to be of non-T-cell origin and several proviral genomes with altered enhancer regions could be found in the tumors. Moreover, reporter constructs with the new tumor-derived variant could not be transactivated by AML1 in cotransfection experiments as could the wild type. These results emphasize the importance of both core/AML1 site I and site II for the pathogenic potential of SL3-3 and at the same time show that second-site alterations can form a viral variant with a substantial pathogenic potential although both AML1 sites I and II are nonfunctional." @default.
• W2148882827 created "2016-06-24" @default.
• W2148882827 creator A5000848633 @default.
• W2148882827 creator A5005671291 @default.
• W2148882827 creator A5005779461 @default.
• W2148882827 creator A5060530664 @default.
• W2148882827 creator A5069723825 @default.
• W2148882827 date "1997-10-01" @default.
• W2148882827 modified "2023-10-17" @default.
• W2148882827 title "Increased lymphomagenicity and restored disease specificity of AML1 site (core) mutant SL3-3 murine leukemia virus by a second-site enhancer variant evolved in vivo" @default.
• W2148882827 cites W123071911 @default.
• W2148882827 cites W1505987103 @default.
• W2148882827 cites W1508122084 @default.
• W2148882827 cites W1510836414 @default.
• W2148882827 cites W1524671781 @default.
• W2148882827 cites W1627653299 @default.
• W2148882827 cites W1723133339 @default.
• W2148882827 cites W1737566264 @default.
• W2148882827 cites W1852045337 @default.
• W2148882827 cites W1852665292 @default.
• W2148882827 cites W1912818092 @default.
• W2148882827 cites W1913342296 @default.
• W2148882827 cites W1916534573 @default.
• W2148882827 cites W1924699518 @default.
• W2148882827 cites W1927891221 @default.
• W2148882827 cites W1931376925 @default.
• W2148882827 cites W1982721874 @default.
• W2148882827 cites W1986334264 @default.
• W2148882827 cites W1987955416 @default.
• W2148882827 cites W1990974448 @default.
• W2148882827 cites W1991766825 @default.
• W2148882827 cites W2003617876 @default.
• W2148882827 cites W2016748666 @default.
• W2148882827 cites W2022272502 @default.
• W2148882827 cites W2026994183 @default.
• W2148882827 cites W2047591593 @default.
• W2148882827 cites W2056560239 @default.
• W2148882827 cites W2060172389 @default.
• W2148882827 cites W2061311391 @default.
• W2148882827 cites W2063426342 @default.
• W2148882827 cites W2066112342 @default.
• W2148882827 cites W2067040747 @default.
• W2148882827 cites W2068728784 @default.
• W2148882827 cites W2068752450 @default.
• W2148882827 cites W2085033687 @default.
• W2148882827 cites W2097391861 @default.
• W2148882827 cites W2108190657 @default.
• W2148882827 cites W2119973182 @default.
• W2148882827 cites W2133010718 @default.
• W2148882827 cites W2134685310 @default.
• W2148882827 cites W2136002296 @default.
• W2148882827 cites W2136931999 @default.
• W2148882827 cites W2139319150 @default.
• W2148882827 cites W2141313102 @default.
• W2148882827 cites W2149662125 @default.
• W2148882827 cites W2159374958 @default.
• W2148882827 cites W2161848417 @default.
• W2148882827 cites W2164389880 @default.
• W2148882827 cites W2168193264 @default.
• W2148882827 cites W2227735589 @default.
• W2148882827 cites W2404041716 @default.
• W2148882827 doi "https://doi.org/10.1128/jvi.71.10.7273-7280.1997" @default.
• W2148882827 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/192069" @default.
• W2148882827 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9311802" @default.
• W2148882827 hasPublicationYear "1997" @default.
• W2148882827 type Work @default.
• W2148882827 sameAs 2148882827 @default.
• W2148882827 citedByCount "24" @default.
• W2148882827 crossrefType "journal-article" @default.
• W2148882827 hasAuthorship W2148882827A5000848633 @default.
• W2148882827 hasAuthorship W2148882827A5005671291 @default.
• W2148882827 hasAuthorship W2148882827A5005779461 @default.
• W2148882827 hasAuthorship W2148882827A5060530664 @default.
• W2148882827 hasAuthorship W2148882827A5069723825 @default.
• W2148882827 hasBestOaLocation W21488828271 @default.
• W2148882827 hasConcept C102906071 @default.
• W2148882827 hasConcept C104317684 @default.
• W2148882827 hasConcept C107824862 @default.
• W2148882827 hasConcept C111936080 @default.
• W2148882827 hasConcept C141231307 @default.
• W2148882827 hasConcept C143065580 @default.
• W2148882827 hasConcept C153911025 @default.
• W2148882827 hasConcept C159047783 @default.
• W2148882827 hasConcept C21784809 @default.
• W2148882827 hasConcept C2522874641 @default.
• W2148882827 hasConcept C2778220731 @default.
• W2148882827 hasConcept C2778431562 @default.
• W2148882827 hasConcept C2779562191 @default.
• W2148882827 hasConcept C54355233 @default.
• W2148882827 hasConcept C86339819 @default.
• W2148882827 hasConcept C86803240 @default.
• W2148882827 hasConceptScore W2148882827C102906071 @default.
• W2148882827 hasConceptScore W2148882827C104317684 @default.
• W2148882827 hasConceptScore W2148882827C107824862 @default.
• W2148882827 hasConceptScore W2148882827C111936080 @default.
• W2148882827 hasConceptScore W2148882827C141231307 @default.
• W2148882827 hasConceptScore W2148882827C143065580 @default.
• W2148882827 hasConceptScore W2148882827C153911025 @default.

• next